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Coordinated enzymatic reactions regulate blood clot
generation. To explore the contributions of various
coagulation enzymes in this process, we utilized a
panel of aptamers against factors VIIa, IXa, Xa,
and prothrombin. Each aptamer dose-dependently
inhibited clot formation, yet none was able to
completely impede this process in highly procoagu-
lant settings. However, several combinations of two
aptamers synergistically impaired clot formation.
One extremely potent aptamer combination was
able to maintain human blood fluidity even during
extracorporeal circulation, a highly procoagulant
setting encountered during cardiopulmonary bypass
surgery. Moreover, this aptamer cocktail could be
rapidly reversed with antidotes to restore normal he-
mostasis, indicating that even highly potent aptamer
combinations can be rapidly controlled. These
studies highlight the potential utility of using sets of
aptamers to probe the functions of proteins inmolec-
ular pathways for research and therapeutic ends.
INTRODUCTION
Fibrin blood clot formation is mediated by a series of enzymatic
reactions that occur on cellular and vascular surfaces. Coagula-
tion proteins circulate in the blood as inactive proteins (zymo-
gens) and upon stimulation are proteolyzed to generate active
enzymes. Traditional coagulation models represent the series
of reactions as a Y-shaped ‘‘cascade’’ with two separate
upstream pathways—the extrinsic and intrinsic pathways—
that ultimately converge into a third, final common pathway (Da-
vie and Ratnoff, 1964;MacFarlane, 1964) (Figure 1). The extrinsic
pathway is stimulated when tissue factor (TF) is released and
forms a complex with circulating activated factor FVII (FVIIa),
while the intrinsic pathway is activated when charged particles
(polyphosphates, collagen, etc.) bind and autoactivate factor
XII. Thrombin is the final enzyme formed in the coagulation
cascade, and the rate of thrombin formation as well as theChemistry & Biology 21, 93amount of thrombin formed directly influences fibrin clot stability
and structure (Wolberg, 2007).
Inappropriate thrombin generation can result in pathological
blood clot formation, termed thrombosis. The treatment of pa-
tients with thrombosis almost always includes the administration
of an anticoagulant therapeutic to impair procoagulant protein
function and prevent blood coagulation. The optimal therapeutic
target and the degree of anticoagulation required vary depend-
ing on the clinical indication. For example, lower levels of antico-
agulation are desired for preventative care in high-risk patients,
while potent anticoagulation is required during surgical proce-
dures, such as cardiopulmonary bypass (CPB) surgery (also
known as open heart surgery), to treat or limit thrombosis.
Genetic studies with knockout mice have been performed to
study the role of coagulation proteins and pathway specific
responses. However, genetically null mice for TF, factor VII
(FVII), factor X (FX), and prothrombin are not viable, making
many studies challenging (Mackman, 2005). Therefore, we
sought to utilize a set of matched anticoagulant agents to inhibit
various human clotting proteins and further clarify the role of
these individual proteins in clot formation in human blood.
Although small molecule anticoagulants have been generated
toward a few coagulation enzymes (i.e., thrombin and activated
factor X, abbreviated FXa), it has been challenging to design
similar compounds toward the remaining enzymes.
Aptamers, or single-stranded oligonucleotides, are nucleic
acid ligands that bind specifically to their therapeutic targets
with high affinity. Modified RNA aptamers can be generated
against several types of therapeutic targets, including soluble
coagulation proteins, by screening combinatorial modified
RNA or DNA oligonucleotide libraries for high affinity binding to
the target protein (Ellington and Szostak, 1990; Tuerk and
Gold, 1990). We have employed this selection method to
generatemodified RNA aptamers to activated coagulation factor
VII (FVIIa) (Layzer and Sullenger, 2007), activated factor IX (FIXa)
(Rusconi et al., 2002), activated factor X (FXa) (Buddai et al.,
2010), and prothrombin (Layzer and Sullenger, 2007). All of the
aptamers bind to both the zymogen and enzyme form of their
target protein (e.g., FVII and FVIIa), and mechanistic studies
with the FIXa, FXa, and prothrombin aptamers indicate that the
aptamers bind a large surface area on the zymogen and enzyme
that is critical for procoagulant protein-protein interactions
(Bompiani et al., 2012; Buddai et al., 2010; Sullenger et al.,5–944, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 935
Figure 1. Diagram of the Enzymatic Reactions that Mediate Blood
Coagulation
The clotting factors circulate in an inactive form (zymogen) and are cleaved
upon activation to result in a mature enzyme (indicated in bold). Traditionally,
the cascade is represented as two main pathways (the intrinsic pathway,
shaded in light gray, and the extrinsic pathway, shaded in medium gray) that
can be stimulated in vitro with specific proteins or chemicals and merge into a
final common pathway (shaded in dark gray). The plasma concentrations of
each zymogen are indicated in parentheses.
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Synergistic Anticoagulant Aptamer Combinations2012). Moreover, we have pioneered the development of two in-
dependent types of antidotes that can rapidly modulate aptamer
anticoagulant function (Oney et al., 2009; Rusconi et al., 2002).
Currently, an optimized version of our FIXa aptamer and its anti-
dote have completed phase two clinical trials, (Cohen et al.,
2010; Povsic et al., 2011). Clinical data indicate that this aptamer
is a potent inhibitor of FIXa function in patients, rapidly anticoa-
gulates subjects within 10 min, and can be quickly modulated
with its antidote (Chan et al., 2008a, 2008b; Dyke et al., 2006).
Here we compare the effects of the FVIIa, FIXa, FXa, and
prothrombin anticoagulant aptamers in several clotting assays
to assess the impact of inhibiting different coagulation factors
at different stages and pathways in the coagulation cascade.
Additionally, we analyzed the effects of simultaneously inhibiting
two proteins within the same or different coagulation pathways
by combining two aptamers targeting different factors. Finally,
to further explore the clinical potential of these anticoagulant
aptamers, we evaluated them in the clinically relevant, highly
prothrombotic setting of ex vivo extracorporeal circulation of
human blood. We observe that individual aptamers cannot
maintain clot-free blood circulation, although a combination of
aptamers can. Moreover, this combination can be rapidly
reversed with antidotes, suggesting that aptamer combinations
may have potential clinical utility when rapid and potent anti-
coagulation is required but safe and rapid reversal of anticoagu-
lation is important. Finally, these studies indicate that the avail-
ability of collections of aptamers that can potently inhibit
individual factors in a branched and interconnected molecular
pathway, such as coagulation, allows for detailed functional
studies of such complex molecular networks.936 Chemistry & Biology 21, 935–944, August 14, 2014 ª2014 ElseviRESULTS
Plasma Clinical Clotting Assays
We compared the anticoagulant effects of inhibiting FVIIa
(Layzer and Sullenger, 2007), FIXa (Rusconi et al., 2002), FXa
(Buddai et al., 2010), and prothrombin (Bompiani et al., 2012)
with 20F-modified RNA aptamers (Figure 2; for aptamer se-
quences, see the Supplemental Experimental Procedures
available online). Mechanistic studies have indicated that these
aptamers bind with high affinity and selectivity to macromolec-
ular binding sites present on both zymogen and enzyme forms
of the individual target proteins and inhibit protein-protein inter-
actions that are essential for coagulation (Bompiani et al., 2012;
Buddai et al., 2010; Sullenger et al., 2012).
The activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT) are plasma clotting assays that are clinically
used to test for abnormalities in the intrinsic and extrinsic coag-
ulation pathways, respectively (Van Cott and Laposata, 2001).
These clinical assays measure the time until clot formation in
platelet poor plasma stimulated with TF (PT assay for the
extrinsic pathway) or the charged particle kaolin (aPTT assay
for intrinsic pathway). Although the FXa and prothrombin ap-
tamers can be tested in both the aPTT and PT assays because
their targets lie in the common pathway, the FVIIa and FIXa ap-
tamers can only be tested in their respective assay because they
target pathway specific enzymes (Figure 1). Dose titrations with
the individual aptamers showed that all of the aptamers pro-
duced dose-dependent anticoagulation and prolonged the
aPTT and PT clotting time to various degrees (Figures 3A and
3B). At saturating concentrations (4 mM), the prothrombin ap-
tamer was the most robust anticoagulant and increased the
aPTT clotting time approximately 18-fold and the PT clotting
time greater than 80-fold (exceeded the assay limit of 999 s).
The FXa aptamer was also a robust anticoagulant, and at satu-
rating concentrations (4 mM) it increased the aPTT clotting time
approximately 11-fold and increased the PT clotting time
approximately 8-fold. At the same saturating dose, the FIXa ap-
tamer increased the aPTT clotting time approximately 5.5-fold,
while the FVIIa aptamer increased the PT clotting time 3-fold
(Figures 3A and 3B).
To determine the effect of inhibiting several proteins in the
coagulation cascade, combinations of two aptamers were also
assessed. Combinations of drugs that inhibit several enzymes
within a biological pathway may synergize; that is, their com-
bined inhibitory effect may exceed the additive inhibitory effects
produced by each inhibitor alone (Berenbaum, 1977). Combina-
tions of two different aptamers at equimolar concentrations were
tested in the plasma clot-based assays. At high concentrations
(R1 mM total RNA), all of the aptamer combinations tested in
the aPTT assay (i.e., FIXa + FXa, FIXa + prothrombin, and
FXa + prothrombin) synergistically prolonged the clotting time
and exceeded the assay maximum of 999 s (Figure 3C; for
synergy statistical analysis, see the Supplemental Experimental
Procedures). Similarly, the FVIIa + FXa combination at high con-
centrations synergistically prolonged the PT clotting time, and at
4 mM total RNA increased the clotting time approximately 50-
fold; however, the FVIIa + prothrombin aptamer combination
did not synergistically increase the PT clotting time, and at
4 mM total RNA only increased the clotting time approximatelyer Ltd All rights reserved
Figure 2. The M-Fold Predicted Secondary Structures of the Four Modified RNA Anticoagulant Aptamers and Their Point Mutants
Point mutants are indicated in bold with dashed lines. The apparent binding affinities of the aptamers are indicated. All four aptamers bind both the zymogen and
enzyme form of the clotting factor target.
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Synergistic Anticoagulant Aptamer Combinations28-fold (Figure 3D). Thus, several specific combinations of two
anticoagulant aptamers result in a synergistic anticoagulant
cocktail that severely retards blood clot formation. Additional
dose-scouring studies with varying molar ratios of the aptamers
can be performed to optimize dosing based on target plasma
concentration.
Thromboelastography
Although the aPTT and PT assays provide basic information
about dose-dependent anticoagulation, these assays are limited
because they are performed in plasma in the absence of plate-
lets. Platelets play a crucial role in clot formation by providing
a membrane surface upon which the clotting factors assemble,
by aggregating and becoming physically incorporated into the
blood clot, and by releasing internal stores of agonists that
amplify the coagulation response (Monroe et al., 2002). There-
fore, we studied the effects of factor inhibition with thromboelas-
tography (TEG), which provides information about the kinetics of
clot formation in whole blood (Reikvam et al., 2009). The TEG
assay uses mechanical motion to quantify the physical proper-
ties of clot formation, including the lag time (the time until clot
formation), the a angle (the rate of clot formation), and the
maximum amplitude (the mechanical strength of the clot formed)
(Figure S1).
When blood was stimulated with the intrinsic pathway acti-
vator kaolin, the FIXa, FXa, and prothrombin aptamers all
produced a dose-dependent effect and impaired clot formation
(Table 1). At a saturating concentration, the FIXa aptamer
increased the lag time, or time to clot initiation (6.9 versus
25.5 min), decreased the rate of clot formation (a angle of 62.4
versus 37.6), and decreased the maximum clot strength (ampli-
tude of 63.5 versus 55.4 mm). The FXa aptamer at a saturating
concentration had a more robust effect and further increased
the lag time (6.9 versus 39.6 min), decreased the a angle (62.4
versus 18), and decreased themaximumamplitude (63.5 versus
39.6 mm). Finally, the prothrombin aptamer at the same concen-
tration increased the lag time (6.9 versus 21.5 min), decreasedChemistry & Biology 21, 93the a angle (62.4 versus 30), and decreased the maximum
amplitude (63.5 versus 49.6 mm) (Table 1).
Because kaolin stimulates blood via the intrinsic pathway
(Figure 1), it is unlikely that the FVIIa aptamer will impair clot
formation with this type of stimulation; thus, we tested this
aptamer in a modified TEG with TF stimulation. TF was diluted
to a final concentration of 0.33 pM to stimulate clotting,
and control baseline assays were simulated with TF-produced
lag times, a angles, and maximum amplitudes comparable
to the normal kaolin baseline parameters (Table 1). At a satu-
rating concentration, the FVIIa aptamer slightly increased the
lag time (4.6 versus 6.6 min), but did not appreciably impact
the a angle (65.2 versus 61.9) or the maximum amplitude
(67.8 versus 63.1 mm) with TF stimulation. A saturating con-
centration of the FIXa aptamer did not increase the lag time
(4.6 versus 4.5 min), decrease the a angle (65.2 versus 66.3),
or decrease the maximum amplitude (67.8 versus 69.1 mm)
with TF stimulation. In contrast, the FXa aptamer at a saturating
concentration increased the lag time (4.6 versus 51.1 min),
decreased the a angle (65.2 versus 21.4), and decreased
the maximum amplitude (67.8 versus 51.1 mm) (Table 1).
Finally, a saturating concentration of the prothrombin aptamer
(5 mM) increased the lag time (4.6 versus 39.4 min), decreased
the a angle (65.2 versus 15.2), and decreased the maximum
amplitude (67.8 versus 36.8 mm) in a TF-stimulated TEG
(Table 1).
To show that inhibition of thrombin generation requires
functional RNA aptamers, we designed and tested point mutant
control RNAs. Rusconi et al. showed that mutating two
conserved nucleotides completely abolished FIXa aptamer
activity, indicating that these nucleotides are crucial for RNA
folding and/or protein binding (Rusconi et al., 2002) (Figure 2).
Similar point mutant controls were also designed for the FXa
and prothrombin aptamers and were previously shown to be
nonfunctional in aPTT and/or PT clotting assays (Bompiani
et al., 2012; Buddai et al., 2010). Likewise, an FVIIa point mutant
was designed that had no significant impact on PT clotting time5–944, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 937
Figure 3. Dose Titrations with Each of the Four Anticoagulant Aptamers in Clinical aPTT and PT Plasma Clotting Assays
(A) Dose titration response with individual aptamers targeting the intrinsic or common pathway in the activated partial thromboplastin time (aPTT) assay.
(B) Dose titration response with the individual aptamers targeting the extrinsic or common pathway in the prothrombin time (PT) assay. The data represent the
mean ± SEM of duplicates; the lines were arbitrarily drawn.
(C) Dose titration for combinations of two aptamers in the aPTT assay.
(D) Dose titration for combinations of two aptamers in the PT assay. The x axis represents the total RNA concentration, where each aptamer is present in an
equimolar concentration. The data represent the mean ± SEM of duplicates; the lines were arbitrarily drawn.
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Synergistic Anticoagulant Aptamer Combinationswhen tested in parallel with the FVIIa aptamer (data not shown).
TEG experiments were performed with these point mutants at
the same concentrations as the functional aptamers to show
that aptamer anticoagulation is specific and not engendered
by high concentrations of modified RNA. As was expected,
none of the point mutant control RNAs had an impact on clot for-
mation stimulated by kaolin or TF (Table 1).
Although the individual aptamers slowed clot formation
as measured by TEG, no single aptamer prevented clot for-
mation for greater than 1 hr following either kaolin or TF
stimulation. Therefore, we tested the effect of aptamer combi-
nations to see if aptamer combinations exert synergistic inhib-
itory effects in whole blood. Anticoagulation with aptamer
combinations FIXa + FXa, FIXa + prothrombin, and FXa +
prothrombin all completely inhibited clot formation by kaolin
stimulation for greater than the maximum time of the TEG
assay, 3 hr (Table 2). In contrast, the FVIIa + FIXa aptamer
combination was not able to prevent clot formation by TF
stimulation for greater than 55 min, and FVIIa + FXa aptamer
anticoagulation only prevented clot formation by TF stimula-
tion for greater than 3 hr in one of the three donors tested
with TF stimulation (Table 2). Control experiments were
performed where each functional aptamer was tested in
combination with the appropriate point mutant control RNA
at the relevant concentrations. As expected, the control com-
binations did not exhibit synergism and anticoagulated plasma
to a degree that was similar to the individual functional ap-
tamers (Table 2).938 Chemistry & Biology 21, 935–944, August 14, 2014 ª2014 ElseviExtracorporeal Circulation
CPB (also known as open heart surgery) is the most prothrom-
botic setting where rapid onset anticoagulation is often required.
During CPB, the patient’s blood is removed from the heart and
siphoned off into a machine (extracorporeal circuit) that replaces
heart and lung function. Potent systemic anticoagulation is
required during CPB to maintain blood fluidity in response to
numerous stimuli (Levi et al., 2011; Yavari andBecker, 2008). Un-
fractionated heparin (UFH), which is a glycosaminoglycan that
targets multiple coagulation factors, and its antidote protamine
are the current standard of care for CPB anticoagulation. How-
ever, both UFH and protamine can cause potentially severe
side effects (Carr and Silverman, 1999; Warkentin, 1999).
To determine if inhibition of coagulation factors with aptamers
could maintain blood fluidity in this highly procoagulant setting,
we performed experiments where human blood was continu-
ously circulated in a miniature model extracorporeal circuit for
2 hr in the presence of various anticoagulants (de Lange et al.,
2007, 2008). The blood is continually circulated from a reservoir
to a membrane via a mechanical roller pump, and as the blood is
circulated it is heated to approximately 33C and supplied with a
mixture of 95%O2 and 5%CO2 (Figure S2). The goal of these ex-
periments was to determine if inhibition of individual or sets of
coagulation factors with aptamer(s) could maintain human blood
fluidity during extracorporeal circulation and successfully
replace UFH. Whole human blood was anticoagulated with the
aptamers or UFH and circulated in the extracorporeal bypass
circuit for 2 hr or until visible clot formation was observed. Ater Ltd All rights reserved
Table 1. Thromboelastography Clot Formation Parameters for Whole Blood Anticoagulated with Various Individual Aptamers and
Stimulated with Either Kaolin or Tissue Factor
Aptamer RNA (mM) Stimulant Lag Time (min) Angle (deg) Max. Amplitude (mm)
None – kaolin 6.9 ± 0.8 62.4 ± 1.6 63.5 ± 0.9
FIXa 0.5 kaolin 22.8 ± 2.0 41.4 ± 0.5 55.4 ± 3.2
1.0 kaolin 25.5 ± 1.8 37.6 ± 7.1 55.4 ± 2.6
2.0 kaolin 29.9 ± 1.4 36.9 ± 2.9 55.9 ± 3.4
FXa 0.5 kaolin 15.6 ± 0.8 40.3 ± 1.4 52.4 ± 1.6
1.0 kaolin 20.6 ± 3.0 28.7 ± 5.0 48.2 ± 3.7
2.0 kaolin 39.6 ± 9.1 18.0 ± 5.9 39.6 ± 4.4
Prothrombin 1.25 kaolin 7.1 ± 1.4 60.4 ± 2.4 62.0 ± 3.0
2.0 kaolin 8.3 ± 2.0 48.1 ± 9.7 56.0 ± 6.3
5.0 kaolin 21.5 ± 4.9 30.0 ± 5.7 49.6 ± 3.6
FIXa mutant 2.0 kaolin 7.3 ± 2.1 58.6 ± 7.8 60.1 ± 5.8
FXa mutant 2.0 kaolin 5.1 ± 0.6 69.7 ± 1.2 65.8 ± 0.8
Prothrombin mutant 5.0 kaolin 6.5 ± 0.4 56.0 ± 4.8 61.9 ± 4.0
None – TF 4.6 ± 0.2 65.2 ± 2.4 67.8 ± 1.2
FVIIa 0.12 TF 4.5 ± 0.6 65.2 ± 5.2 63.0 ± 3.7
0.25 TF 5.1 ± 1.2 62.4 ± 3.7 64.0 ± 2.8
0.50 TF 6.6 ± 0.8 61.9 ± 3.3 63.1 ± 2.0
FIXa 1.00 TF 4.5 ± 0.5 66.3 ± 1.3 69.1 ± 1.5
FXa 2.00 TF 51.1 ± 12.2 21.4 ± 7.3 51.1 ± 1.6
Prothrombin 5.00 TF 39.4 ± 5.0 15.2 ± 2.5 36.8 ± 1.4
FIXa mutant 1.00 TF 2.7 ± 0.4 69.0 ± 4.8 67.2 ± 1.6
FXa mutant 2.00 TF 3.9 ± 0.2 68.5 ± 0.5 67.9 ± 0.7
Prothrombin mutant 5.00 TF 2.7 ± 0.2 72.3 ± 0.7 66.1 ± 1.4
FVIIa mutant 0.50 TF 3.1 ± 0.1 67.8 ± 3.8 67.2 ± 0.7
The data represent the mean ± SEM of three independent experiments with blood from three different healthy donors. TF, tissue factor; min, minutes;
deg, degrees; mm, millimeters; max. amplitude, maximum amplitude.
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mine the activated clotting time plus (ACT+) on a point of care
device that is utilized to monitor anticoagulant activity during
CBP. Similar to the aPTT and PT clotting time assays, the
ACT+ assay measures the clotting time; however, the ACT+
assay contains a mixture of activators (silica and kaolin) and
measures clotting time in whole blood, rather than platelet
poor plasma.
As expected, UFH-mediated anticoagulation (5 U/mL) main-
tained blood fluidity and circuit patency for 2 hr. The ACT+ clot-
ting time was increased from an average of 124 s (average donor
baseline) to an averagemaximal clotting time of 426 s (Table S1),
which is within the suggested range of 400–480 s for CPB (Cohn
and Edmunds, 2008). At the end of the 2-hr experiment, the
circuit was flushed with PBS and no visible clotting was
observed. Scanning electron microscopy (SEM) of the oxygen-
ator membrane shows that there was no microscopic fibrin
deposition and minimal cellular adhesion to the membrane (Fig-
ure 4A; for SEM preparation details, see the Supplemental
Experimental Procedures).
In sharp contrast to UFH, inhibition of no single coagulation
factor with an aptamer prevented clot formation in the circuit.
Macroscopic clots were formed either within the reservoir, on
the oxygenator membrane, or at both sites within 2 hr.
Compared to the average donor baseline ACT+ clot timeChemistry & Biology 21, 93(124 s), FIXa aptamer anticoagulation did not increase the
clotting time (102 s), FXa aptamer anticoagulation increased
the ACT+ to amaximum of 213 s, and prothrombin aptamer anti-
coagulation increased the ACT+ to a maximum of 365 s
(Table S1). Due to its limited impact on thrombin generation in
the previous in vitro assays, the FVIIa aptamer was not analyzed
ex vivo. Scanning electron micrographs of the oxygenator
membrane from circuits anticoagulated with the FIXa, FXa, or
prothrombin aptamers show fibrin deposition on the membrane
(Figures 4B, 4C, and 4D). Thus, inhibition of individual coagula-
tion factors with the various aptamers does not provide a satis-
factory degree of anticoagulation to prevent clot formation in a
human extracorporeal circuit.
Because UFH anticoagulates blood by inhibiting several
procoagulant enzymes (Bedsted et al., 2003; Beeler et al.,
1979; Olson et al., 1992), we hypothesized that combinations
of anticoagulant aptamers may more effectively mimic UFH
anticoagulation in the ex vivo circuit. The three potent aptamer
combinations that kept whole blood fluid in a TEG for greater
than 3 hr (FIXa + FXa, FIXa + prothrombin, and FXa + prothrom-
bin aptamers; Table 2) were tested in the ex vivo circuit. Simulta-
neous inhibition of FIXa and FXa with aptamers failed to maintain
the ex vivo circuit clot free as macroscopic blood clots in the
reservoir and on the oxygenator membrane were apparent after
the blood was circulated for 2 hr. This combination increased the5–944, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 939
Table 2. Thromboelastography Clot Formation Parameters for Whole Blood Anticoagulated with Various Aptamer Combinations and
Stimulated with Kaolin or Tissue Factor
Aptamer 1 Aptamer 2 Stimulant Lag Time (min) Angle (deg) Max. Amplitude (mm)
None none kaolin 7.6 ± 0.6 60.8 ± 0.4 63.8 ± 1.3
None none TF 4.6 ± 0.2 65.2 ± 2.4 67.8 ± 1.2
FVIIa (0.5 mM) FIXa (1.0 mM) TF 29.7 ± 12.6 40.8 ± 9.2 60.8 ± 1.5
FVIIa (0.5 mM) FXa (2.0 mM) TF 75.5 ± 2.8a 8.5 ± 1.5a 43.2 ± 6.6a
FIXa (1.0 mM) FXa (2.0 mM) kaolin no clot formation within 3 hr
FIXa (1.0 mM) prothrombin (5.0 mM) kaolin no clot formation within 3 hr
FXa (0.5 mM) prothrombin (5.0 mM) kaolin no clot formation within 3 hr
FVIIa (0.5 mM) FIXa mutant (1.0 mM) TF 5.6 ± 0.2 54.1 ± 4.9 67.5 ± 1.5
FXa (2.0 mM) FVIIa mutant (0.5 mM) TF 45.5 ± 11.3 23.7 ± 10.1 51.7 ± 6.1
FXa (2.0 mM) FIXa mutant (1.0 mM) kaolin 77.8 ± 36.8 16.7 ± 11.2 31.8 ± 15.4
Prothrombin (5.0 mM) FIXa mutant (1.0 mM) kaolin 42.1 ± 1.0 17.2 ± 1.4 41.6 ± 1.4
FXa (0.5 mM) prothrombin mutant (5.0 mM) kaolin 26.7 ± 5.1 34.3 ± 8.9 52.2 ± 3.4
The data represent the mean ± SEM of three independent experiments with blood from three different healthy donors. TF, tissue factor; min, minutes;
deg, degrees; mm, millimeters; max. amplitude, maximum amplitude; hr, hours.
aClotting was observed within 3 hr for only two of the three donors; the data represent the mean ± SEM of these two donors.
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Synergistic Anticoagulant Aptamer CombinationsACT+ from an average baseline of 124 s to a maximum of 205 s
(Table S1). Similarly inhibition of FIXa and prothrombin with this
aptamer combination failed to maintain the circuit clot free as
visible blood clots appeared on the oxygenator membrane.
This aptamer combination increased the ACT+ clotting to a
maximum of 368 s (Table S1).
However, inhibition of FXa and prothrombin using an aptamer
combination successfully prevented clot formation in the circuit
for greater than 2 hr in three independent experiments with blood
from three different donors. This combination prolonged the
ACT+ clotting time from an average of 124 s to a maximal time
of 462 s (Table S1). Scanning electron micrographs of the
oxygenator membrane from circuits treated with FXa + pro-
thrombin aptamer anticoagulation show minimal fibrin deposi-
tion and cellular adhesion, similar to the UFH heparin membrane
(Figure 4E). Thus, simultaneous inhibition of FXa and prothrom-
bin with the combination of FXa and prothrombin aptamers
can emulate UFH and robustly anticoagulate human blood dur-
ing circulation in an extracorporeal bypass circuit.
Antidote Reversal of the FXa + Prothrombin Aptamer
Combination
We have previously described two independent methods of
anticoagulant aptamer control with either a complementary
matched oligonucleotide antidote (Rusconi et al., 2002) or a uni-
versal antidote (Oney et al., 2009). Because our data here show
that several aptamer combinations result in extremely robust
anticoagulation, we wanted to show that synergistic aptamer
combinations can be effectively controlled with an antidote,
thereby potentially improving drug safety. Therefore, we tested
antidote reversal of the FXa + prothrombin aptamer combination
that successfully maintained blood fluidity in the extracorporeal
bypass circuit.
Whole blood was anticoagulated with the FXa + prothrombin
aptamers at a dose that prevented clot formation for more than
3 hr in a TEG, and various antidotes were subsequently added.
Both protamine and the b-cyclodextrin containing polymer940 Chemistry & Biology 21, 935–944, August 14, 2014 ª2014 Elsevi(CDP) were tested for their ability to function as a universal anti-
dote by simultaneously reversing both aptamers in combination
(Oney et al., 2009). After anticoagulation with the aptamer com-
bination for 1 hr, addition of a 4-fold molar excess of protamine
(22 mmM) compared to the aptamers resulted in stable clot forma-
tion within an average of 14 min, while CDP (50 mg) was even
more effective at reversing anticoagulation and resulted in stable
clot formation within an average of 11 min (Table 3). Additionally,
an antidote cocktail containing a 3-fold molar excess of the FXa
antidote oligonucleotide and a 2-fold molar excess of the
prothrombin antidote oligonucleotide (Bompiani et al., 2012)
reversed anticoagulation and resulted in clot formation within
an average of 12 min (Table 3). Therefore, aptamer reversal
with CDP or antidote oligonucleotides appears to be rapid, as
the blood clotted within a similar timeframe as blood that has
never been anticoagulated (within 8 min). Thus, although the
FXa + prothrombin aptamer combination is an extremely potent
anticoagulant cocktail that can replace UFH anticoagulation in
an ex vivo circuit and maintain blood fluidity, the aptamer com-
bination can also be rapidly reversed with either a universal anti-
dote or a combination of oligonucleotide antidotes.
DISCUSSION
The coagulation cascade represents an intricate and critical
biological system. Coagulation has been extensively character-
ized and modeled over the past 100 years and represents an
ideal paradigm to study the global effects of perturbing the sys-
tem in a myriad of ways. Our panel of anticoagulant aptamers
represents a valuable tool to study changes in clot formation
and thrombin generation when individual or combinations of
coagulation enzymes are functionally removed from the system
by titrating in the appropriate inhibitory aptamer.
Our data indicate that the individual aptamers each have a
unique dose-dependent impact on clot formation in various
in vitro assays. Although all of the aptamers specifically bind to
their therapeutic target with low-nanomolar affinities (Bompianier Ltd All rights reserved
Figure 4. Scanning Electron Micrographs of Extracorporeal Circuit Oxygenator Membranes from Circuits with Various Anticoagulants
Micrograph of a membrane from an extracorporeal circuit anticoagulated with (A) UFH (5 U/mL), (B) FIXa aptamer (1 mM), (C) FXa aptamer (2 mM), (D) prothrombin
aptamer (5 mM), and (E) FXa (0.5 mM) + prothrombin aptamers (5 mM). The images are representative of data obtained from three different areas of the membrane.
Scale bar, 500 mm (1003) and 50 mm (1,0003).
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Synergistic Anticoagulant Aptamer Combinationset al., 2012; Buddai et al., 2010; Layzer and Sullenger, 2007; Sul-
lenger et al., 2012) (Figure 2), the in vitro plasma data indicate
that to produce optimal anticoagulation, enough aptamer must
be added to saturate the protein target in plasma (Figure 3).
For example, although the prothrombin binds to human pro-
thrombin with a Kd of 10 nM, micromolar concentrations are
required to saturate prothrombin, which has an estimated con-
centration of 1.4 mM in human plasma (Bompiani et al., 2012).
Consequentially, lower concentrations of aptamers targeting
‘‘upstream’’ less abundant coagulation factors (i.e., FVII and
FIX) are required for saturation compared to aptamers targeting
‘‘downstream’’ more abundant coagulation factors (i.e., FX and
prothrombin) (Figures 1 and 3).
Clinical studies have shown that the FIXa aptamer generates a
hemophilia-B-like state by inhibiting greater than 99% of FIXa
activity in vivo (Povsic et al., 2011). Moreover, this aptamer-anti-
dote pair sufficiently anticoagulated blood to allow for neonatal
swine to be placed upon cardiopulmonary bypass for up to
60 min (Nimjee et al., 2006), and phase 2b clinical trials indicate
that this anticoagulant system can effectively anticoagulate pa-
tients undergoing elective percutaneous coronary intervention
(or ‘‘angioplasty’’) (Cohen et al., 2010). However, our data clearly
show that this aptamer has a limited anticoagulant effect in the
presence of high TF andmay therefore be less effective for treat-
ing clinical indications that are associated with high levels of TF
(Tables 1 and 2). Although it is commonly believed that coagula-
tion is mainly initiated by the contact/intrinsic pathway during
extracorporeal circulation (Fuhrer et al., 1986; WachtfogelChemistry & Biology 21, 93et al., 1989, 1993), several studies have indicated that TF stimu-
lation plays a major role (Boisclair et al., 1993; Burman et al.,
1994; Kappelmayer et al., 1993). Correspondingly, the FIXa
aptamer was not able to anticoagulate adult human blood during
ex vivo extracorporeal circulation for 2 hr to an extent that
maintained the circuit clot free (Figure 4B) and may therefore
not be ideal as a sole anticoagulant for CPB in adult humans.
The impact of inhibiting two specific procoagulant proteases
was analyzed by assessing the effect of combining two indi-
vidual aptamers. Combining two drugs that inhibit proteins
within the same pathway has the potential to synergistically
inhibit downstream responses (Berenbaum, 1977). Interestingly,
although some of the aptamer cocktails resulted in synergistic
anticoagulation in vitro, several aptamer combinations were
not synergistic (Figure 3; Table 2). Generally speaking, aptamer
combinations that inhibit two nonsequential enzymatic reactions
(i.e., FVIIa + prothrombin) appeared less synergistic compared
to combinations that inhibit sequential steps (i.e., FXa + pro-
thrombin). Inhibiting two sequential enzymes may more effec-
tively prevent signal amplification, resulting in more robust
anticoagulation.
Bench top clotting assays such as the aPTT and PT are
routinely used in the clinic to rapidly assess coagulation defi-
ciencies in patients, where clotting factor deficiencies result in
increased clotting times. Similarly, these tests can be applied
in a research environment to rapidly assess the function of anti-
coagulant therapeutics. However, these assays have a number
of limitations that should be considered. Plasma-based assays5–944, August 14, 2014 ª2014 Elsevier Ltd All rights reserved 941
Table 3. Thromboelastography Clot Formation Parameters for Whole Blood Anticoagulated with the FXa and Prothrombin Aptamer
Combination Subsequently Reversed with Either Oligonucleotide or Universal Antidotes
Aptamer Stimulant Antidote Lag Time (min) Angle (deg) Max. Amplitude (mm)
None kaolin none 7.9 ± 0.4 62.0 ± 0.8 65.4 ± 0.35
FXa (0.5 mM) +
prothrombin (5 mM)
kaolin none no clot formation within 3 hr
protamine (22 mM) 13.1 ± 1.0 47 ± 2.5 53.1 ± 1.8
CDP (50 mg) 10.2 ± 1.4 53.4 ± 1.8 59.7 ± 1.7
FXa + prothrombin oligonucleotide
antidotes (1.5 mM + 10 mM)
11.1 ± 1.5 52.6 ± 3.5 59.6 ± 1.2
The data represent themean ± SEMof three independent experiments with blood from three different healthy donors. Bloodwas stimulated with kaolin
and anticogulated with 0.5 mM FXa aptamer and 5 mM prothrombin aptamer. Antidotes were added after 1 hr of anticoagulation, and TEG parameters
were measured. Min, minutes; deg, degrees; mm, millimeters; max. amplitude, maximum amplitude; CDP, b-cyclodextrin containing polymer.
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one component of the hemostatic system. Additionally, stimula-
tion with extreme concentrations of TF or artificial agents, such
as kaolin, is not representative of clotting activation in vivo. While
these assays can be used tomonitor anticoagulant function, they
are not predictive of function in varying clinical environments.
Thus, anticoagulant regimes must be evaluated in experiments
closely mimicking their clinical application. As such, we utilized
a model of blood circulation to mimic extracorporeal circulation
during cardiopulmonary bypass to test one specific clinical
application of our technology.
Strikingly, no individual aptamer was able to totally prevent
clot formation in the ex vivo circuit for 2 hr. The current regimen
for cardiopulmonary bypass, UFH, anticoagulates blood by
inhibiting several coagulation factors (FIXa, FXa, and thrombin)
(Bedsted et al., 2003; Beeler et al., 1979; Olson et al., 1992);
therefore, we hypothesized that a combination of anticoagulant
aptamers may better mimic UFH anticoagulation during CPB.
Of the three synergistic aptamer combinations that were tested
in the ex vivo circuit, only the FXa + prothrombin aptamer com-
bination was able to totally prevent fibrin deposition on the
oxygenator membrane and was comparable to treatment with
UFH (Figure 4E). This aptamer combination may be optimal
because it inhibits the two steps in the common pathway of
coagulation, rather than pathway specific steps (Figure 1). Addi-
tional studies can be performed to see if adding a third aptamer
decreases the doses of aptamers required or improves other
parameters that are clinically relevant during CPB, such as
inflammation markers or complement activation.
Although currently a number of anticoagulant and antiplatelet
agents are available, most of these drugs do not produce an
optimal level of anticoagulation for extracorporeal bypass circu-
lation and/or cannot be controlled with an antidote (Murphy and
Marymont, 2007). Our data clearly demonstrate that a potent ap-
tamer combination can effectively anticoagulate blood yet be
rapidly reversed with several types of antidotes (Table 3). Based
upon the ease with which they can be used in combination and
safely controlled, we believe that aptamers may have broad clin-
ical applications for treating thrombosis in the acute care setting.
SIGNIFICANCE
Coagulation is a concerted series of feed forward and
backward enzymatic reactions that has been extensively942 Chemistry & Biology 21, 935–944, August 14, 2014 ª2014 Elsevimodeled, although researchers still debate the role of the
various enzymes in this interconnected pathway. Knockout
mice for several clotting proteins cannot be generated
because the proteins are essential for survival, and the cre-
ation and availability of small molecule drugs for several of
these enzymes is beyond most researchers. In contrast,
the recent availability of aptamers to an increasing number
of proteins led us to explore whether panels of aptamers
might represent useful chemical probes to study complex
biological pathways, such as blood coagulation. We utilized
a set of four aptamers to study the effect of targeting
different enzymes involved in coagulation: FVIIa, FIXa, FXa,
and prothrombin. Comparative studies with in vitro coagula-
tion assays indicate that each individual aptamer has a
particular impact on clot formation, with aptamers targeting
downstream enzymes (i.e., FXa and prothrombin) engen-
dering more robust anticoagulation.
Inhibiting two proteins within the same biological
cascade has the potential to result in synergistic
inhibition, and anticoagulants are typically not used
in combination because such synergy can lead to uncon-
trollable bleeding. However, robust anticoagulation is
required during some clinical surgical procedures to limit
pathological blood clot formation. Several combinations
of anticoagulant aptamers act synergistically. The pair of
aptamers targeting factor Xa (FXa) and prothrombin can
even keep human blood clot free in the highly procoagulant
setting of extracorporeal blood circulation used during
cardiopulmonary bypass surgery. Importantly, the antico-
agulant effect of even this potent pair of aptamers could
be counteracted by the addition of two different types of
antidotes to blood, thereby minimizing the risk of ex-
cessive bleeding, if needed. Thus, aptamers appear to be
useful tools to probe the function(s) of individual and com-
binations of proteins in biological pathways, such as blood
coagulation.
EXPERIMENTAL PROCEDURES
Materials
Normal pooled platelet poor plasma (PPP) was purchased from George King
Biomedical. PBS, tetramethylsilane, and formaldehyde were purchased from
Sigma-Aldrich. Ethanol was purchased from EMD Millipore, and glutaralde-
hyde was purchased from TCI America. UFH and protamine sulfate were pur-
chased from APP Pharmaceuticals. CDP was a generous gift from Jeremyer Ltd All rights reserved
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reagents were purchased from Trinity BioTech.
Plasma Clotting Assays
The aPTT and PT assays were performed on a model ST4 mechanical coagul-
ometer (Diagnostica Stago) as previously described (Nimjee et al., 2009). For
the aPTT, 50 ml of normal human PPP was incubated with 50 ml TriniClot
aPTT S (Trinity BioTech) at 37C for 5 min. Aptamer(s) (5 ml) was added, the
mixture was incubated at 37C for another 5 min, and CaCl2 (50 ml) was added
to initiate the assay. For the PT, 50 ml of normal human PPPwas incubatedwith
5 ml of aptamer(s) at 37C for 5 min. TriniClot PT Excel reagent (Trinity BioTech)
(100 ml) was added to initiate the reaction. Assays with a combination of two
aptamers contain an equimolar concentration of each individual aptamer,
and the data shown are the total RNA concentration.
Thromboelastography
Blood was drawn from healthy, consenting volunteers under a Duke University
Institutional Review Board approved protocol, where blood draw procedures
were in accordance with institutional guidelines. Blood was anticoagulated
with 3.2% sodium citrate, and citrated whole blood (320 ml) was mixed with
anticoagulant (heparin or aptamers) (10 ml) and kaolin (Haemonetics) (10 ml)
or calibrated automated thrombography platelet-rich plasma reagent (Diag-
nostica Stago, 0.33 rM TF final) (10 ml) was added to stimulate clotting.
CaCl2 (20 ml) was immediately added to overcome the citrate, the mixture
was added to a plain disposable plastic TEG cup (Haemonetics), and the
assay was run according to the manufacturer’s instructions. Clot formation
at 37C was measured with a Thromboelastograph Analyzer (Haemonetics)
until a stable clot was formed (i.e., a maximum amplitude was reached) or
for 3 hr with the aptamer combinations. The time lag time, a angle, and
maximum amplitude were automatically calculated by the TEG Analytical Soft-
ware version 4.2.3 (Haemonetics).
For the antidote reversal TEGs, whole blood was anticoagulated with a com-
bination of the FXa (0.5 mM) and prothrombin (5 mM) aptamers for 1 hr as
described, antidote (10 ml) was added, and the assay was continued until a
stable clot was formed. At 1 hr after assay initiation, a 4-fold molar excess of
protamine (22 mM) was added, 50 mg of CDP was added, or a 2-fold molar
excess of the prothrombin aptamer antidote oligonucleotide (10 mM) in combi-
nation with a 3-fold molar excess of the FXa aptamer antidote oligonucleotide
(1.5 mM) was added.
Extracorporeal Membrane Circuit Oxygenation
The extracorporeal circuit consisted of a sample line, custom-designed 8 ml
Plexiglas venous reservoir, a mechanical roller pump (MasterFlex; Cole-
Parmer Instrument), and a custom-designed small-volume oxygenator that
are all connected by MasterFlex precision silicone tubing (Cole-Parmer Instru-
ment) (de Lange et al., 2007, 2008). The 4 ml priming volume oxygenator is
comprised of two Plexiglas shells (12.8 cm 3 12.8 cm 3 2.7 cm) that cover
a disposable three-layer artificial diffusion membrane comprised of hollow
polypropylene fibers glued together in a crosswise fashion. The surface area
available for gas exchange is 558 cm2. To prevent heat loss, one of the shells
has an integrated heat exchanger, and the temperature was maintained at
approximately 33C with a circulating water bath system (Gaymar Industries).
A MEAS reusable temperature probe (Model 451, Measurement Specialties)
was inserted into the reservoir to continuously measure the temperature,
and an in-line flow probe (2N806 flow probe and T208 volume flowmeter; Tran-
sonics Systems) was used to continuously measure the blood flow. The circuit
blood O2 level was maintained at 95%, and the CO2 was maintained at 5%.
The circuit was primedwith PBS at a flow rate of 50ml/min for approximately
30 min. Blood was drawn from healthy, consenting volunteers under a Duke
University Institutional Review Board approved protocol, where blood draw
procedures were in accordance with institutional guidelines. The blood was
anticoagulated with 3.2% sodium citrate, and approximately 25 ml of citrated
bloodwas incubatedwith 500 ml of anticoagulant (i.e., UFH or aptamer) at 37C
for 5 min. The PBS was drained from the circuit, and the blood was added and
circulated at a rate of 50 ml/min with 95% O2/5% CO2 at approximately 33
C.
CaCl2 (660 ml, 6.45mM final) was added to overcome the citrate and initiate the
experiment. Blood samples (200 ml) were withdrawn from the baseline
citrated blood (no aptamer) and from the circuit reservoir at 5, 30, 60, 90,Chemistry & Biology 21, 93and 120 min post circuit initiation or until visible clot formation. ACT+ assays
(ITC) were immediately runwith a Hemochron Jr. signature point of care device
(ITC Nexus Dx). To analyze the citrated baseline ACT+ values, 6.45 mM CaCl2
was added to approximately 100 ml of blood, the mixture was incubated for
30 s at ambient temperature, and the assay was run according to themanufac-
turer’s instructions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
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